A rationale for the activity profile of arylpiperazinylthioalkyls as 5-HT1A-serotonin and α1-adrenergic receptor ligands
- 31 May 2010
- journal article
- Published by Elsevier BV in European Journal of Medicinal Chemistry
- Vol. 45 (5), 1927-1934
- https://doi.org/10.1016/j.ejmech.2010.01.034
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Innovative approaches for the development of antidepressant drugs: Current and future strategiesNeuroRX, 2005
- Derivatives as 5HT1A Receptor Ligands-Past and PresentCurrent Medicinal Chemistry, 2005
- Arylpiperazine Derivatives Acting at 5-HT1A ReceptorsCurrent Medicinal Chemistry, 2002
- New 5-HT1A receptor agonists possessing 1,4-Benzoxazepine scaffold exhibit highly potent anti-ischemic effectsBioorganic & Medicinal Chemistry Letters, 2001
- The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the ratBrain Research, 1999
- Multiple Serotonin Receptors: Too Many, Not Enough, or Just the Right Number?Neuroscience & Biobehavioral Reviews, 1997
- Prospects for Improved AntidepressantsJournal of Medicinal Chemistry, 1995
- Chapter 1. Recent Progress in Serotonin (5-HT)1A Receptor ModulatorsPublished by Elsevier BV ,1995
- A 3 dimensional model for 5-HT1A-receptor agonists based on stereoselective methyl-substituted and conformationally restricted analogs of 8-hydroxy-2-(dipropylamino)tetralinJournal of Medicinal Chemistry, 1991
- The genomic clone G-21 which resembles a β-adrenergic receptor sequence encodes the 5-HT1A receptorNature, 1988